Kerry Sharp, a member of the Penningtons Manches award-winning life sciences team, was featured in the September issue of Finance Monthly as its Advisor of the Month. This was in recognition of her involvement with Adaptimmune Limited’s multi-million USD strategic collaboration with Glaxosmithkline, one of the largest deals of 2014.
In her interview, Kerry explained the challenges of this deal: “With any collaboration and licensing agreement, the challenge is always to balance the requirement of both parties including where problems develop with the technology or the collaboration. This is particularly difficult with new technologies and therapies given the relative uncertainty of success or path to regulatory approval and commercialisation and, in particular, what happens to the IP rights should problems develop or the market change.”
Kerry's article can be viewed on page 64 here.